Background: S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (DKK-1), marker of bone remodelling, is also implicated in the process of syndesmophyte formation in ankylosing spondylitis. The aim of our study was to evaluate plasma levels of S100A4 in patients with axial spondyloarthritis and to determine the potential association of S100A4 with disease severity, clinical manifestations and with bone changes in a cross-sectional study. Methods: Fifty-eight patients with axial spondyloarthritis and 40 healthy controls were studied. Biological samples were analysed for S100A4 and Dickkopf-1. Disease activity was assessed according to the Bath Ankylosing Spondylitis Disease Activity Index. C-reactive protein (CRP) was used as a marker of inflammation. Radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). Results: The plasma levels of S100A4 were significantly higher in patients with axial spondyloarthritis compared to heathy controls (p < 0.0001). The levels of S100A4 were higher in early stages of the disease and lower in patients with the presence of syndesmophytes (p = 0.009). Furthermore, we found weak but significant inverse correlation of plasma S100A4 with the mSASSS (r = - 0.363, p = 0.030). Levels of S100A4 were negatively associated with disease duration (r = - 0.404, p = 0.002) and positively with Dickkopf-1 binding capacity (r = 0.312, p = 0.023). Conclusions: This is the first study showing elevated circulating levels of S100A4 in patients with axial spondyloarthritis, particularly in early stages of the disease prior to spinal involvement, and its significantly lower levels in patients with syndesmophytes. The role of S100A4 in the pathogenesis of axial spondyloarthritis can be suggested.

Department of Neuroscience and Pharmacology Faculty of Health Sciences University of Copenhagen Copenhagen Denmark

Institute of Rheumatology Prague Czech Republic

Institute of Rheumatology Prague Czech Republic 2Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc20005255

003      

CZ-PrNML

005      

20210121102123.0

007      

ta

008      

200511s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1186/s41927-019-0110-7 $2 doi

035    __

$a (PubMed)32021963

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Šumová, Barbora $u 1Institute of Rheumatology, Prague, Czech Republic.

245    10

$a S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity / $c B. Šumová, LA. Cerezo, H. Hulejová, K. Prajzlerová, M. Tomčík, K. Bubová, J. Štěpán, M. Filková, T. Kropáčková, M. Grigorian, K. Pavelka, J. Vencovský, L. Šenolt,

520    9_

$a Background: S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (DKK-1), marker of bone remodelling, is also implicated in the process of syndesmophyte formation in ankylosing spondylitis. The aim of our study was to evaluate plasma levels of S100A4 in patients with axial spondyloarthritis and to determine the potential association of S100A4 with disease severity, clinical manifestations and with bone changes in a cross-sectional study. Methods: Fifty-eight patients with axial spondyloarthritis and 40 healthy controls were studied. Biological samples were analysed for S100A4 and Dickkopf-1. Disease activity was assessed according to the Bath Ankylosing Spondylitis Disease Activity Index. C-reactive protein (CRP) was used as a marker of inflammation. Radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). Results: The plasma levels of S100A4 were significantly higher in patients with axial spondyloarthritis compared to heathy controls (p < 0.0001). The levels of S100A4 were higher in early stages of the disease and lower in patients with the presence of syndesmophytes (p = 0.009). Furthermore, we found weak but significant inverse correlation of plasma S100A4 with the mSASSS (r = - 0.363, p = 0.030). Levels of S100A4 were negatively associated with disease duration (r = - 0.404, p = 0.002) and positively with Dickkopf-1 binding capacity (r = 0.312, p = 0.023). Conclusions: This is the first study showing elevated circulating levels of S100A4 in patients with axial spondyloarthritis, particularly in early stages of the disease prior to spinal involvement, and its significantly lower levels in patients with syndesmophytes. The role of S100A4 in the pathogenesis of axial spondyloarthritis can be suggested.

655    _2

$a časopisecké články $7 D016428

700    1_

$a Cerezo, Lucie Andrés $u 1Institute of Rheumatology, Prague, Czech Republic.

700    1_

$a Hulejová, Hana $u 1Institute of Rheumatology, Prague, Czech Republic.

700    1_

$a Prajzlerová, Klára $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Tomčík, Michal $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Bubová, Kristýna $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Štěpán, Jan $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Filková, Mária $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Kropáčková, Tereza $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Grigorian, Mariam $u 3Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

700    1_

$a Pavelka, Karel $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Vencovský, Jiří $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

700    1_

$a Šenolt, Ladislav $u 1Institute of Rheumatology, Prague, Czech Republic. 2Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

773    0_

$w MED00203203 $t BMC rheumatology $x 2520-1026 $g Roč. 4, č. - (2020), s. 13

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32021963 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20200511 $b ABA008

991    __

$a 20210121102121 $b ABA008

999    __

$a ind $b bmc $g 1524185 $s 1095310

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 4 $c - $d 13 $e 20200131 $i 2520-1026 $m BMC rheumatology $n BMC Rheumatol $x MED00203203

LZP    __

$a Pubmed-20200511